Journals / Health Sciences Quarterly / 2021 / Cilt: 1 - Sayı: 1

Long-term effect of intravenous iron carboxymaltose treatment on oxidative stress in women with iron deficiency anemia

Pages
3–10
Publication Date
2021-04-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Intravenous iron replacement prompts oxidative stress at hour 1 of infusion in adults with anemia but this increase resolves partially in the following 30 day

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study aims to clarify the effects of intravenous iron supplementation on biomarkers for oxidative stress in women with iron deficiency anemia.
📊
Key Findings & Data:This is a cross-sectional review of 40 healthy women and 40 women who underwent intravenous iron treatment due to anemia.
💡
Conclusion & Impact:Intravenous iron replacement prompts oxidative stress at hour 1 of infusion in adults with anemia but this increase resolves partially in the following 30 day
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Anemia · iron · oxidative stress

Abstract

This study aims to clarify the effects of intravenous iron supplementation on biomarkers for oxidative stress in women with iron deficiency anemia. This is a cross-sectional review of 40 healthy women and 40 women who underwent intravenous iron treatment due to anemia. Biochemical markers for oxidative stress were determined for both healthy controls and anemic patients. These markers were also evaluated at hour 1 and day 30 of intravenous iron treatment. The patients with anemia had significantly higher catalase activity and total oxidant status (TOS) but significantly lower nitrate and total anti-oxidant status (TAS) than the healthy controls (p=0.0245, p<0.0001, p=0.0437 and p<0.0001 respectively). At hour 1 of intravenous iron treatment, nitrate, nitrite, nitric oxide, total thiol and TAS values were significantly lower and TOS values were significantly higher than those before the administration of treatment (p=0.0322, p=0.0003, p=0.0005, p<0.0001, p<0.0001 and p=0.004). At day 30 of intravenous iron treatment, catalase activity, nitrate, total thiol and TOS values were significantly lower than those before the administration of treatment (p=0.0332, p=0.0015, p=0.0391 and p<0.0001 respectively) and at hour 1 of treatment (p=0.0498, p<0.0001, p=0.0004 and p<0.0001 respectively). At day 30 of intravenous iron treatment, nitric oxide and TAS values were significantly higher than those before the administration of treatment (p=0.0480 and p=0.001 respectively) and at hour 1 of treatment (p<0.0001 for both). Intravenous iron replacement prompts oxidative stress at hour 1 of infusion in adults with anemia but this increase resolves partially in the following 30 day

🔖

Cite This Article

PEKTAŞ, G., KIRLI, İ. (2021). Long-term effect of intravenous iron carboxymaltose treatment on oxidative stress in women with iron deficiency anemia. Health Sciences Quarterly, Cilt: 1 - Sayı: 1, 3–10. https://ajindex.com/articles/836574

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. AUERBACH, M., ADAMSON, J.W. 2016. How we diagnose and treat iron deficiency anemia. American Journal of Hematology 91(1):31–38.
  2. AUERBACH, M., DELOUGHERY, T. 2016. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematology 2016(1):57–66.
  3. AUERBACH, M., MACDOUGALL, I. 2017. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodialysis International 21(1):S83–S92. AVNI, T., BIEBER, A., GROSSMAN, A., GREEN, H., LEIBOVICI, L., GAFTER-GVILI, A. 2015. The safety of intravenous iron preparations. Mayo Clinic Proceedings 90(1):12–23.
  4. BAILIE, G.R., SCHULER, C., LEGGETT, R.E., LI, H., LI, H.D., PATADIA, H., LEVIN, R. 2013. Oxidative effect of several intravenous iron complexes in the rat. BioMetals 26(3):473–478.
  5. BRAMAN, R.S., HENDRIX, S.A. 1989. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium(III) reduction with chemiluminescence detection. Analytical Chemistry 61(24):2715–2718.
  6. BURATTI, P., GAMMELLA, E. RYBINSKA, I. CAIRO, G., RECALCATI, S. 2015. Recent advances in iron metabolism. Medicine & Science in Sports & Exercise 47(8):1596–1604.
  7. CAMASCHELLA, C. 2015. Iron deficiency: new insights into diagnosis and treatment. Hematology 2015(1):8–13.
  8. CAPPELLINI, M.D., MUSALLAM, K.M., TAHER, A.T. 2020. Iron deficiency anaemia revisited. Journal of Internal Medicine 287(2):153–170.
  9. CHAPARRO, C.M., SUCHDEV, P.S. 2019. Anemia epidemiology, pathophysiology, and etiology in low‐ and middle‐income countries. Annals of the New York Academy of Sciences 1450(1):15–31.
  10. DAN DUNN, J., ALVAREZ, L.A., ZHANG, X., SOLDATI, T. 2015. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biology 6:472–485.
  11. DELOUGHERY, T.G. 2019. Safety of oral and intravenous iron. Acta Haematologica 142(1):8–12.
  12. EDUARDO-TOBLLI, J., CAO, G., OLIVERI, L., ANGEROSA, M. 2012. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflammation & Allergy - Drug Targets 11(1):66–78.
  13. EREL, O. 2005. A new automated colorimetric method for measuring total oxidant status. Clinical Biochemistry 38(12):1103–1111.
  14. EREL, O. 2004. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clinical Biochemistry 37(4):277–285.
  15. EREL, O. 1998. Automated measurement of serum ferroxidase activity. Clinical Chemistry 44(11):2313–2319.
  16. EREL, O., NESELIOGLU, S. 201